Efficient Human Hematopoietic Cell Transduction Using RD114- and GALV-Pseudotyped Retroviral Vectors Produced in Suspension and Serum-Free Media

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Human Gene Therapy

• Publication date

  2009-07-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/hum.2009.001PMID 19453219PMCID PMC2861952
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

  2009cited by this paper
• Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture.

  2008cited by this paper
• Gene therapy of inherited diseases.

  2008cited by this paper
• The suicide gene therapy challenge: how to improve a successful gene therapy approach.

  2007influential reference
• Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation.

  2007cited by this paper
• Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media

  2007influential reference
• A First-In-Human Clinical Trial of Adoptive Therapy Using CD19-Specific Chimeric Antigen Receptor Re-Directed T-Cells for Recurrent/Refractory Follicular Lymphoma.

  2007cited by this paper
• Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1

  2006cited by this paper
• Downstream processing of oncoretroviral and lentiviral gene therapy vectors.

  2006cited by this paper
• Functional Assessment of the Engraftment Potential of Gammaretrovirus-Modified CD34+ Cells, Using a Short Serum-Free Transduction Protocol

  2006cited by this paper
• Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

  2006cited by this paper
• Retroviral vector production using suspension‐adapted 293GPG cells in a 3L acoustic filter‐based perfusion bioreactor

  2006influential reference
• Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation.

  2005cited by this paper
• Improved transduction of human sheep repopulating cells by retrovirus vectors pseudotyped with feline leukemia virus type C or RD114 envelopes.

  2005cited by this paper
• Gene modification strategies to induce tumor immunity.

  2005cited by this paper
• Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-based vectors from stable producer cells.

  2005cited by this paper
• Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.

  2004cited by this paper
• Characterization of HIV-1 vectors with gammaretrovirus envelope glycoproteins produced from stable packaging cells

  2004influential reference
• State‐of‐the‐art of the production of retroviral vectors

  2004influential reference
• Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD/SCID/beta -microglobulin-/- repopulating mobilized human peripheral blood CD34+ cells.

  2003influential reference
• Targeting tumours with genetically enhanced T lymphocytes

  2003cited by this paper
• Concentrated RD 114-pseudotyped MFGS-gp 91 phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD / SCID / 2-microglobulin / repopulating mobilized human peripheral blood CD 34 cells

  2003cited by this paper
• Concentrated RD114-Pseudotyped MFGS-gp91 Vector Achieves High Levels of Functional Correction of the Chronic Granulomatous Disease Oxidase Defect in NOD/SCID/β2m-/- Repopulating Mobilized Human Peripheral Blood CD34 Cells Running head: RD114 MFGS-gp91 correction of X-CGD Scientific section heading:

  2003influential reference
• Gene Therapy of X-Linked Severe Combined Immunodeficiency

  2002cited by this paper
• Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning

  2002influential reference
• Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates.

  2002influential reference
• High Translation Efficiency Is Mediated by the Encephalomyocarditis Virus Internal Ribosomal Entry Sites if the Natural Sequence Surrounding the Eleventh AUG Is Retained

  2002cited by this paper
• Haematopoietic cell transplantation as immunotherapy

  2001cited by this paper
• Analysis of 4070A envelope levels in retroviral preparations and effect on target cell transduction efficiency.

  2000cited by this paper
• Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

  2000influential reference
• Retroviral preparations derived from PA317 packaging cells contain inhibitors that copurify with viral particles and are devoid of viral vector RNA.

  2000cited by this paper
• Dose-dependent transduction of vesicular stomatitis virus G protein-pseudotyped retrovirus vector into human solid tumor cell lines and murine fibroblasts.

  1999cited by this paper
• Development of Improved Adenosine Deaminase Retroviral Vectors

  1998cited by this paper
• Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes.

  1997cited by this paper
• Gene Transfer into Marrow Repopulating Cells: Comparison Between Amphotropic and Gibbon Ape Leukemia Virus Pseudotyped Retroviral Vectors in a Competitive Repopulation Assay in Baboons

  1997cited by this paper
• Gene transfer into marrow repopulating cells: comparison between amphotropic and gibbon ape leukemia virus pseudotyped retroviral vectors in a competitive repopulation assay in baboons.

  1997cited by this paper
• The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction.

  1996cited by this paper
• Gene Transfer

  1995influential reference
• Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus

  1991cited by this paper

• Modeling immunotherapies in live 3D human cancer tissue bioreactors

  2026cites this paper
• Baboon endogenous retrovirus (ERV) envelope pseudotyped lentiviral vectors outperform human ERV lentivectors for transduction of T, B, NK and HSPCs.

  2026cites this paper
• CAR-adapted PIK3CD base editing enhances T cell anti-tumor potency

  2026cites this paper
• Ablation of prostaglandin E2 signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours.

  2026cites this paper
• Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors

  2025cites this paper
• Retrovirus-based manufacturing of chimeric antigen receptor-modified T cells for cancer therapy research.

  2025cites this paper
• Retroviral Vector Technology for Gene Therapy: History, Current Landscape, and Future Prospects.

  2025cites this paper
• Site-specific genome engineering of primary human natural killer cells for programmable anti-tumor function

  2025cites this paper
• Development of KoRV-pseudotyped lentiviral vectors for efficient gene transfer into freshly isolated immune cells

  2024cites this paper
• Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma

  2024cites this paper
• Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia

  2024cites this paper
• The resting and ligand-bound states of the membrane-embedded human T-cell receptor–CD3 complex

  2024cites this paper
• A convenient viral transduction based method for advanced multi-engineering of primary human (CAR) T-cells

  2024cites this paper
• Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies.

  2024cites this paper
• Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy

  2023cites this paper
• Genetic ablation of adhesion ligands averts rejection of allogeneic immune cells

  2023cites this paper
• Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia

  2023cites this paper
• Insights into product and process related challenges of lentiviral vector bioprocessing

  2023cites this paper
• Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma

  2023cites this paper
• Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

  2023cites this paper
• Novel suspension retroviral packaging cells generated by transposition using transposase encoding mRNA advance vector yields and enable production in bioreactors

  2023cites this paper
• Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia

  2023cites this paper
• Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors

  2023influential citation
• Neoantigen quality predicts immunoediting in survivors of pancreatic cancer

  2022cites this paper
• The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer.

  2022cites this paper
• Efficient clinical-grade γ-retroviral vector purification by high-speed centrifugation for CAR T cell manufacturing

  2022cites this paper
• Efficient CRISPR-Cas9-mediated mutagenesis in primary human B cells for identifying plasma cell regulators

  2022cites this paper
• PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models

  2022cites this paper
• Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function

  2022cites this paper
• Transwell migration assay to interrogate human CAR-T cell chemotaxis

  2022cites this paper
• Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors

  2022cites this paper
• A TCR-like CAR Promotes Sensitive Antigen Recognition and Controlled T-cell Expansion Upon mRNA Vaccination

  2022cites this paper
• Generation of Redirected Engineered Human Chimeric Antigen Receptor (CAR) T Cells.

  2022cites this paper
• CD81 costimulation skews CAR transduction toward naive T cells

  2022cites this paper
• Manufacturing of CAR-T Cells: The Assembly Line

  2022cites this paper
• Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors

  2021cites this paper
• A modular and controllable T cell therapy platform for acute myeloid leukemia

  2021cites this paper
• A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein

  2021cites this paper
• Lentiviral Vector Bioprocessing

  2021cites this paper
• T cells armed with the C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours

  2021cites this paper
• Depletion of T cells via Inducible Caspase 9 Increases Safety of Adoptive T-Cell Therapy Against Chronic Hepatitis B

  2021cites this paper
• Acoustofluidic-mediated molecular delivery to human T cells with a three-dimensional-printed flow chamber.

  2021cites this paper
• Efficient production of Moloney murine leukemia virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein

  2020cites this paper
• Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?

  2020cites this paper
• Combination of C-C chemokine receptor 8 and dominant-negative TGF-β-receptor 2 expression in T cells for adoptive T cell therapy of solid cancer

  2020cites this paper
• Understanding Gamma Delta T Cell Multifunctionality - Towards Immunotherapeutic Applications

  2020cites this paper
• Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?

  2020cites this paper
• T cell receptor grafting allows virological control of Hepatitis B virus infection.

  2019cites this paper
• Generation of High-Titer Self-Inactivated γ-Retroviral Vector Producer Cells

  2019cites this paper
• GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR

  2018influential citation
• Vesiculovirus G protein-based stable cell lines for continuous lentiviral vector production

  2018influential citation
• Chimeric antigen receptor (CAR) T-cell immunotherapy for MUC1-positive breast cancer

  2018cites this paper
• Effective NY-ESO-1–specific MHC II–restricted T cell receptors from antigen-negative hosts enhance tumor regression

  2018cites this paper
• Translating the combination of gene therapy and tissue engineering for treating recessive dystrophic epidermolysis bullosa.

  2018cites this paper
• Present Situation of Viral Vector Manufacturing and Ways to Overcome Potential Barriers in View of the Routine Large Scale Production and Use of Viral Vectors

  2017influential citation
• Masked Chimeric Antigen Receptor for Tumor-Specific Activation.

  2017cites this paper
• CAR-T – The Future Promising Therapy for CLL: A Mix between Cell Therapy, Gene Therapy and Immune Oncology

  2017cites this paper
• Développement d'un traitement pour l'épidermolyse bulleuse dystrophique récessive combinant la thérapie génique et le génie tissulaire

  2016cites this paper
• From Adoptive Immunity to CAR Therapy: An Evolutionary Perspective

  2016cites this paper
• Clinical manufacturing of CAR T cells: foundation of a promising therapy

  2016cites this paper
• Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen

  2016cites this paper
• Impacts of human LDLR overexpression on the production of a VSVG-pseudotyped lentiviral vector

  2015cites this paper
• Large-scale Clinical-grade Retroviral Vector Production in a Fixed-Bed Bioreactor

  2015cites this paper
• CAR therapy: the CD19 paradigm.

  2015cites this paper
• Susceptibility of domestic animals to a pseudotype virus bearing RD-114 virus envelope protein.

  2015cites this paper
• Influence of HEK293 metabolism on the production of viral vectors and vaccine.

  2015cites this paper
• Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition

  2015cites this paper
• Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies

  2015cites this paper
• Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.

  2015cites this paper
• T-Cell Engineering and Expansion — GMP Issues

  2014cites this paper
• HEK293-Based Production Platform for γ-Retroviral (Self-Inactivating) Vectors: Application for Safe and Efficient Transfer of COL7A1 cDNA

  2014cites this paper
• Floriane transfer into early-cytokine-stimulated and resting HSCs Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene

  2014cites this paper
• Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs.

  2014cites this paper
• Towards more successful gene therapy clinical trials for β-thalassemia.

  2013cites this paper
• Heterogeneity, Self-Renewal, and Differentiation of Hematopoietic Stem Cells

  2012cites this paper
• Rapid Production of Clinical-Grade Gammaretroviral Vectors in Expanded Surface Roller Bottles Using a “Modified” Step-Filtration Process for Clearance of Packaging Cells

  2011cites this paper
• The Ongoing Challenge of Hematopoietic Stem Cell-Based Gene Therapy for β-Thalassemia

  2011cites this paper
• Major challenges for gene therapy of thalassemia and sickle cell disease.

  2010cites this paper
• Production of retroviral vectors: review.

  2010cites this paper